Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
Open Access
- 1 December 2020
- journal article
- editorial
- Published by Elsevier BV in Gastroenterology
- Vol. 159 (6), 2013-2018.e7
- https://doi.org/10.1053/j.gastro.2020.07.064
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
This publication has 33 references indexed in Scilit:
- Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's DiseaseGastroenterology, 2014
- Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?Clinical Gastroenterology and Hepatology, 2013
- Endoscopic Skipping of the Distal Terminal Ileum in Crohn's Disease Can Lead to Negative Results From IleocolonoscopyClinical Gastroenterology and Hepatology, 2012
- Magnetic resonance imaging for evaluation of Crohnʼs diseaseInflammatory Bowel Diseases, 2011
- Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's diseaseGut, 2009
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- A reproducible grading scale for histological assessment of inflammation in ulcerative colitisGut, 2000
- Microscopic activity in ulcerative colitis: what does it mean?Gut, 1991
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisThe New England Journal of Medicine, 1987
- Treatment of Ulcerative Colitis with Local HydrocortisoneBMJ, 1956